| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRAC |
| Uniprot No | Q96KF2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-57aa |
| 氨基酸序列 | MLCAHFSDQG PAHLTTSKSA FLSNKKTSTL KHLLGETRSD GSACNSGISG GRGRKIP |
| 预测分子量 | 5,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PRAC(前列腺癌相关抗原)重组蛋白的3篇参考文献示例(注：以下文献信息为虚构示例，实际文献请通过学术数据库查询)：
---
1. **文献名称**：*Expression and Purification of Recombinant PRAC Protein for Immunotherapeutic Applications*
**作者**：Smith J. et al.
**摘要**：本研究报道了PRAC重组蛋白在大肠杆菌中的高效表达及纯化方法，验证了其抗原性，并证明其可诱导特异性T细胞反应，为前列腺癌疫苗开发提供基础。
2. **文献名称**：*Functional Characterization of PRAC in Prostate Cancer Cell Proliferation*
**作者**：Lee H. et al.
**摘要**：通过重组PRAC蛋白体外实验，发现其可抑制前列腺癌细胞增殖并诱导凋亡，提示其作为治疗靶点的潜力，并阐明了相关信号通路机制。
3. **文献名称**：*Structural Analysis of Recombinant PRAC Protein Using Cryo-EM*
**作者**：Zhang R. et al.
**摘要**：利用冷冻电镜解析了PRAC重组蛋白的三维结构，揭示了其与抗体结合的关键表位，为基于结构的药物设计提供了依据。
---
**建议**：实际研究中，可通过PubMed、Web of Science等平台以“PRAC recombinant protein”、“PRAC prostate cancer”等关键词检索最新文献。
**Background of PRAC Recombinant Protein**
PRAC (Prostate Cancer Antigen) recombinant protein is a biologically engineered molecule derived from the PRAC gene, which is predominantly expressed in prostate tissue and linked to prostate cancer biology. Initially identified through genomic studies, the PRAC gene encodes a small, secreted protein hypothesized to play roles in cellular differentiation, immune modulation, and tumor microenvironment interactions. Its restricted expression in healthy prostate and elevated levels in certain cancers, particularly prostate malignancies, have made it a subject of interest in oncology and molecular biology.
Recombinant PRAC protein is produced using biotechnological platforms, such as *E. coli* or mammalian expression systems, enabling large-scale synthesis with high purity and consistency. This approach ensures the protein retains functional epitopes for research or therapeutic applications. Its recombinant form allows scientists to study PRAC's mechanisms—such as its potential involvement in cancer cell proliferation, apoptosis, or immune evasion—in controlled experimental settings.
Clinically, PRAC recombinant protein has been explored as a biomarker for prostate cancer diagnosis or prognosis. Additionally, its immunogenic properties have spurred investigations into PRAC-based vaccines or immunotherapies aimed at eliciting targeted anti-tumor immune responses. Recent studies also suggest roles beyond oncology, including potential functions in reproductive biology due to its expression in placental and testicular tissues.
Despite promising avenues, challenges remain, including elucidating its precise molecular interactions and validating clinical utility. Ongoing research aims to decode PRAC's multifaceted roles and harness its recombinant form for therapeutic innovation, positioning it as a compelling candidate in precision medicine and cancer therapeutics.
×
